Cell Interactions in Three Dimensional Tissue Culture
三维组织培养中的细胞相互作用
基本信息
- 批准号:7734733
- 负责人:
- 金额:$ 151.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Activated LymphocyteAcyclovirAddressAffectAmyloid FibrilsBindingCCR5 geneCD3 AntigensCD8B1 geneCXCR4 geneCell CommunicationCell CountCell-Free SystemCellsChronicClinicalClinical TrialsColorectalComplexCultured CellsCyclophilinsCytomegalovirusDNADNA-Directed DNA PolymeraseDataDendritic CellsDevelopmentDown-RegulationEndogenous FactorsEnzymesEventEvolutionFlow CytometryGoalsGreen Fluorescent ProteinsHIVHIV-1HLA-DR AntigensHerpesviridaeHumanHuman Herpesvirus 6IL2RA geneIL3RA geneITGAX geneImmuneImmunologic Deficiency SyndromesImmunophenotypingInfectionIntegration Host FactorsInterferon Gamma/Interleukin-2Interleukin-1 betaInterleukin-15LeadLifeLymphoid TissueMediatingMemoryMicrobeModelingMyelogenousOutcomeParasitesPathogenesisPatientsPeptidylprolyl IsomerasePharmaceutical PreparationsPhosphoric Monoester HydrolasesPhosphotransferasesPlayPreventionProductionProstaticRNA-Directed DNA PolymeraseRecombinantsReverse TranscriptionRoleSeminal fluidSexual TransmissionSignal TransductionSimplexvirusSiteSmall Inducible Cytokine A3SystemT-Cell DepletionT-LymphocyteTestingTherapeuticTissuesTonsilTonsillar TissueToxoplasma gondiiUp-RegulationVaginaVariantViralViral PathogenesisVirusVirus DiseasesVirus Replicationbasecellular targetingconceptcytokinedeoxyguanosine triphosphatedesignhuman tissuein vivoinhibitor/antagonistlymph nodesmacrophagepathogenpreventresponsesimulationstromal cell-derived factor-1betatissue culturetransmission processvirus pathogenesis
项目摘要
Non-HIV microbes affect HIV pathogenesis by mechanisms that have yet to be elucidated. In general, host factors, in particular imunoactivation together with viral evolution are factors that largely determine the course of HIV infection and non-HIV microbes may affect these phenomena. We addressed these problems by studying pathogenesis of HIV and its interaction with other viruses in various human tissues infected ex vivo.
1. Critical role of tissue activation in HIV infection
First, we focused on the role of immunoactivation in HIV-1 pathogenesis. Paradoxically, HIV infection that leads to immunodeficiency depends on tissue immunoactivation. We propose that immune activation in secondary lymphoid tissues is central to the pathogenesis of immune deficiency in chronic HIV-1 infection. In vivo it may predict the pace of CD4 depletion and the onset of clinical immune deficiency. Earlier we found that in HIV-infected lymph nodes there is a significant perturbation of cytokine secretion in particular of interleukin-1beta, interleukin-2, interferon-gamma and interleukin-15 as well as MIP-1alpha and SDF-1beta. Also, there was a profound upregulation of the activation marker, CD38, in naive, central memory, and effector CD4+ and CD8+ T cells. To study this phenomenon we used a system of blocks of human lymphoid tissue and of cervico-vaginal tissue cultured ex vivo. HIV-1 infection was associated with the activation of both HIV-1-infected and uninfected (bystanders) T cells in infected tissues creating a vicious cycle that facilitates HIV own production by creating new cellular targets for viral infection and therefore contributing to the T cell depletion.
2. Effect of non-HIV pathogens on HIV infection in human lymphoid tissue
Co-pathogens may contribute to immunoactivation, thus affecting HIV disease. We investigated HIV response to coinfection with some of HIV-1 copathogens, human cytomegalovirus (HCMV or HHV-5) and the cellular parasite Toxoplasma gondii.
This required optimization of the human tonsillar tissue to support hCMV replication. hCMV DNA, flow cytometry of viral-positive cells and expression of the green fluorescent protein CMVPT30-gfp in a recombinant strain of hCMV demonstrated that hCMV readily replicated in tissue blocks. Immunophenotyping of HCMV-infected cells showed the preferential infection of activated lymphocytes (CD3+ HLA-DR+ and CD3+ CD25+) and also of plasmocytoid and myeloid dendritic cells (CD3- CD123+ CD11c+). The number of these cells significantly increased in HIV-1-coinfected tissues. Accordingly, HCMV replication was enhanced 2- to-3 fold. This upregulation occurred in tissues infected with either CXCR4- or CCR5-utilizing HIV-1. Thus, HIV-1 creates new targets for hCMV, which may explain the strong association of hCMV with HIV-1 infection in vivo. Human lymphoid tissue ex vivo also provides a model to study HIV interaction with non-viral HIV pathogens in particular of a parasite Toxoplasma gondii. We found that live T. gondii preferentially inhibits CCR5-utilizing HIV-1 replication in coinfected tissues. This effect was reproduced by treatment of the tissue blocks with recombinant C-18, a T. gondii-encoded cyclophilin that binds to CCR5. Thus, T.gondii may influence the outcome of viral infection by preferentially suppressing CCR5-utilizing HIV-1 variants.
These studies revealed that HIV- copathogens may differentially generate positive and negative signals for HIV replication, thus affecting selection of particular HIV variants eventually changing the course of HIV disease.
3. Up- and downregulation of HIV-1 replication in cervico-vaginal tissue
Endogenous factors also generate such signals. We participated in the identification of a semen factor that facilitates HIV- replication, and we showed that it upregulates HIV replication in infected T cells, macrophages, ex vivo human tonsillar tissues, and cervico-vaginal tissues. This factor consists of naturally occurring fragments of the abundant semen marker prostatic acidic phosphatase, which form amyloid fibrils. Thus, these fibrils may play an important role in sexual transmission of HIV and could represent new targets for its prevention. Whether non-HIV microbes affect formation of such fibrils now has to be investigated.
Natural infection with non-HIV-1 microbes can be used for development of new anti-HIV strategies. Here, we exploit the unique ability of herpesvirus (HHV) kinases to phosphorylate acyclovir (ACV), the first step in transforming this otherwise inert compound into an inhibitor of HHV DNA polymerases. Surprisingly, we found that in a cell-free system, phosphorylated ACV directly suppresses HIV reverse transcriptase. We showed that HIV-1 RT incorporates ACV-TP into the nascent HIV-1 DNA chain with a level of efficiency similar to that of its natural equivalent dGTP. Incorporation of ACV-TP results in the formation of a dead-end complex and traps RT at the site of termination leading to the complete termination of reverse transcription. Accordingly, we found that in tissues coinfected with HHVs that are capable of phosphorylating ACV, HIV-1 was inhibited. That was demonstrated in cervico-vaginal tissue as well as in other tissues, where the critical events of HIV-1 pathogenesis and transmission occurs in vivo, tonsils, lymph nodes, and colorectal tissue. Various HHVs, including the ubiquitous HHV-6 detected in all but one tissue ex vivo, may mediate HIV-1 suppression by ACV. No anti-HIV ACV activity was detected in either the HHV-free tissue or in HHV-free cell cultures. However, when HHV-6-infected cells were added to the HIV-1-infected (HHV-free) cell cultures, ACV became a potent suppressor of HIV-1 replication. In summary, the following mechanism seems to be responsible for ACV suppression of HIV-1 in human tissues ex vivo, the majority of which carry one or several HHVs, including HHV-6: ACV is monophosphorylated by herpesviral enzymes in HHV-infected cells and is then cellular kinases convert it into ACV-TP, which suppresses HIV in coinfected tissues by inhibiting HIV-1 RT. Our results suggest that ACV may be therapeutically beneficial for various HIV-1-infected patients, since the majority of humans are already infected with various HHVs that transform ACV at least during reactivation. However, clinical trials are needed to test this concept in vivo. In general, the combination of ACV with an endogenous HHV infection to suppress HIV may constitute a new principle of anti-HIV therapy; a binary weapon in which one inert component is converted by another, endogenous component, into an active therapeutic compound.
非HIV微生物影响HIV发病机制的机制尚未阐明。一般来说,宿主因素,特别是免疫激活和病毒进化在很大程度上决定了HIV感染的过程,而非HIV微生物可能影响这些现象。我们通过研究艾滋病毒的发病机制及其在体外感染的各种人体组织中与其他病毒的相互作用来解决这些问题。
项目成果
期刊论文数量(25)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Real-time PCR assay of individual human immunodeficiency virus type 1 variants in coinfected human lymphoid tissues.
对共感染的人淋巴组织中的个体人类免疫缺陷病毒 1 型变种进行实时 PCR 测定。
- DOI:10.1128/jcm.41.5.2126-2131.2003
- 发表时间:2003
- 期刊:
- 影响因子:9.4
- 作者:Ito,Yoshinori;Grivel,Jean-Charles;Margolis,Leonid
- 通讯作者:Margolis,Leonid
A naturally occurring variation in the proline-rich region does not attenuate human immunodeficiency virus type 1 nef function.
富含脯氨酸区域中自然发生的变异不会减弱人类免疫缺陷病毒 1 型 nef 功能。
- DOI:10.1128/jvi.78.18.10197-10201.2004
- 发表时间:2004
- 期刊:
- 影响因子:5.4
- 作者:Rucker,Elke;Munch,Jan;Wildum,Steffen;Brenner,Matthias;Eisemann,Jutta;Margolis,Leonid;Kirchhoff,Frank
- 通讯作者:Kirchhoff,Frank
Interactions between human immunodeficiency virus type 1 and vaccinia virus in human lymphoid tissue ex vivo.
离体人体淋巴组织中 1 型人类免疫缺陷病毒与牛痘病毒之间的相互作用。
- DOI:10.1128/jvi.00326-07
- 发表时间:2007
- 期刊:
- 影响因子:5.4
- 作者:Vanpouille,Christophe;Biancotto,Angelique;Lisco,Andrea;Brichacek,Beda
- 通讯作者:Brichacek,Beda
Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants.
- DOI:10.1084/jem.192.10.1491
- 发表时间:2000-11-20
- 期刊:
- 影响因子:0
- 作者:Kawamura T;Cohen SS;Borris DL;Aquilino EA;Glushakova S;Margolis LB;Orenstein JM;Offord RE;Neurath AR;Blauvelt A
- 通讯作者:Blauvelt A
Noninfectious X4 but not R5 human immunodeficiency virus type 1 virions inhibit humoral immune responses in human lymphoid tissue ex vivo.
非感染性 X4(而非 R5)人类免疫缺陷病毒 1 型病毒颗粒会抑制离体人体淋巴组织中的体液免疫反应。
- DOI:10.1128/jvi.78.13.7061-7068.2004
- 发表时间:2004
- 期刊:
- 影响因子:5.4
- 作者:Fitzgerald,Wendy;Sylwester,AndrewW;Grivel,Jean-Charles;Lifson,JeffreyD;Margolis,LeonidB
- 通讯作者:Margolis,LeonidB
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Leonid B. Margolis其他文献
Dynamics of lymphocytic composition of human atherosclerotic plaques ex vivo
- DOI:
10.1016/j.atherosclerosis.2017.06.198 - 发表时间:
2017-08-01 - 期刊:
- 影响因子:
- 作者:
Daria Vorobyeva;Anna Lebedeva;Murad Vagida;Oxana Ivanova;Eugeny Felker;Vladimir Gontarenko;Alexander Shpektor;Leonid B. Margolis;Elena Vasilieva - 通讯作者:
Elena Vasilieva
Different subpopulations of monocytes in platelet-monocyte complexes in patients with acute coronary syndrome
- DOI:
10.1016/j.atherosclerosis.2017.06.522 - 发表时间:
2017-08-01 - 期刊:
- 影响因子:
- 作者:
Natalia Pinegina;Marina Louinova;Murad Vagida;Alexander Shpektor;Elena Vasilieva;Leonid B. Margolis - 通讯作者:
Leonid B. Margolis
Leonid B. Margolis的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Leonid B. Margolis', 18)}}的其他基金
Cell Interactions in Three Dimensional Tissue Culture
三维组织培养中的细胞相互作用
- 批准号:
8351142 - 财政年份:
- 资助金额:
$ 151.07万 - 项目类别:
Cell Interactions in Three Dimensional Tissue Culture
三维组织培养中的细胞相互作用
- 批准号:
7208910 - 财政年份:
- 资助金额:
$ 151.07万 - 项目类别:
Cell Interactions in Three Dimensional Tissue Culture
三维组织培养中的细胞相互作用
- 批准号:
8149276 - 财政年份:
- 资助金额:
$ 151.07万 - 项目类别:
Cell Interactions in Three Dimensional Tissue Culture
三维组织培养中的细胞相互作用
- 批准号:
8941463 - 财政年份:
- 资助金额:
$ 151.07万 - 项目类别:
Cell Interactions in Three Dimensional Tissue Culture
三维组织培养中的细胞相互作用
- 批准号:
7594176 - 财政年份:
- 资助金额:
$ 151.07万 - 项目类别:
Viral transmission and pathogenesis in human tissues
人体组织中的病毒传播和发病机制
- 批准号:
10007512 - 财政年份:
- 资助金额:
$ 151.07万 - 项目类别:
Cell Interactions in Three Dimensional Tissue Culture
三维组织培养中的细胞相互作用
- 批准号:
6992849 - 财政年份:
- 资助金额:
$ 151.07万 - 项目类别:
Cell Interactions In Three Dimensional Tissue Culture
三维组织培养中的细胞相互作用
- 批准号:
6541163 - 财政年份:
- 资助金额:
$ 151.07万 - 项目类别:
相似海外基金
DEVELOPMENT OF A NOVEL ANTIVIRAL TO TREAT AND PREVENT ACYCLOVIR RESISTANCE IN HUMAN OCULAR HERPES KERATITIS
开发一种新型抗病毒药物来治疗和预防人眼疱疹性角膜炎的阿昔洛韦耐药性
- 批准号:
9255235 - 财政年份:2017
- 资助金额:
$ 151.07万 - 项目类别:
Establishment of rapid diagnosis system of acyclovir resistant varicella zoster virus
抗阿昔洛韦水痘带状疱疹病毒快速诊断系统的建立
- 批准号:
15K19594 - 财政年份:2015
- 资助金额:
$ 151.07万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Long-Term Herpes Simplex Virus-1 Suppression by Continuous Acyclovir Delivery
通过连续阿昔洛韦给药来长期抑制单纯疱疹病毒 1
- 批准号:
8101508 - 财政年份:2011
- 资助金额:
$ 151.07万 - 项目类别:
Sustained release acyclovir for prophylaxis of genital herpes
缓释阿昔洛韦预防生殖器疱疹
- 批准号:
7619774 - 财政年份:2009
- 资助金额:
$ 151.07万 - 项目类别:
INTRAVENOUS ACYCLOVIR TREATMENT FOR POSTHERPETIC NEURALGIA
静脉注射阿昔洛韦治疗带状疱疹后神经痛
- 批准号:
7377812 - 财政年份:2006
- 资助金额:
$ 151.07万 - 项目类别:
INTRAVENOUS ACYCLOVIR TREATMENT FOR POSTHERPETIC NEURALGIA
静脉注射阿昔洛韦治疗带状疱疹后神经痛
- 批准号:
7200592 - 财政年份:2005
- 资助金额:
$ 151.07万 - 项目类别:
SHEDDING AFTER BEGINNING ACYCLOVIR TREATMENT HERPES SIMPLEX VIRUS TYPE 2 (HSV-2)
开始阿昔洛韦治疗 2 型单纯疱疹病毒 (HSV-2) 后脱落
- 批准号:
7198863 - 财政年份:2005
- 资助金额:
$ 151.07万 - 项目类别: